Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
Add more filters










Publication year range
1.
J Pharmacol Toxicol Methods ; 81: 128-35, 2016.
Article in English | MEDLINE | ID: mdl-27071954

ABSTRACT

UNLABELLED: Cardiovascular (CV) toxicity and related attrition are a major challenge for novel therapeutic entities and identifying CV liability early is critical for effective derisking. CV safety pharmacology studies in rats are a valuable tool for early investigation of CV risk. Thorough understanding of data analysis techniques and statistical power of these studies is currently lacking and is imperative for enabling sound decision-making. METHODS: Data from 24 crossover and 12 parallel design CV telemetry rat studies were used for statistical power calculations. Average values of telemetry parameters (heart rate, blood pressure, body temperature, and activity) were logged every 60s (from 1h predose to 24h post-dose) and reduced to 15min mean values. These data were subsequently binned into super intervals for statistical analysis. A repeated measure analysis of variance was used for statistical analysis of crossover studies and a repeated measure analysis of covariance was used for parallel studies. Statistical power analysis was performed to generate power curves and establish relationships between detectable CV (blood pressure and heart rate) changes and statistical power. Additionally, data from a crossover CV study with phentolamine at 4, 20 and 100mg/kg are reported as a representative example of data analysis methods. RESULTS: Phentolamine produced a CV profile characteristic of alpha adrenergic receptor antagonism, evidenced by a dose-dependent decrease in blood pressure and reflex tachycardia. Detectable blood pressure changes at 80% statistical power for crossover studies (n=8) were 4-5mmHg. For parallel studies (n=8), detectable changes at 80% power were 6-7mmHg. Detectable heart rate changes for both study designs were 20-22bpm. DISCUSSION: Based on our results, the conscious rat CV model is a sensitive tool to detect and mitigate CV risk in early safety studies. Furthermore, these results will enable informed selection of appropriate models and study design for early stage CV studies.


Subject(s)
Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/physiopathology , Data Interpretation, Statistical , Pharmacology/statistics & numerical data , Safety/statistics & numerical data , Adrenergic alpha-Antagonists/toxicity , Animals , Blood Pressure/drug effects , Body Temperature/drug effects , Consciousness , Cross-Over Studies , Dose-Response Relationship, Drug , Heart Rate/drug effects , Male , Motor Activity/drug effects , Phentolamine/toxicity , Rats , Rats, Wistar , Research Design , Telemetry
2.
Drug Chem Toxicol ; 38(3): 266-71, 2015.
Article in English | MEDLINE | ID: mdl-25156279

ABSTRACT

Remeron (Mirtazapine) is an antidepressant drug which exerts its action by blocking presynaptic α-2-adrenergic receptors and postsynaptic serotonin types 2 and 3 receptors. In this in vitro analysis, human peripheral blood lymphocytes was treated by remeron (10, 25, 40 and 55 µg/mL) for 24 hours and 48 hours periods, then it was attempted to study of genotoxic and cytotoxic effects of the substance on human peripheral blood lymphocytes by some tests such as sister chromatid exchange (SCE), chromosomal abnormalities (CA) and micronucleus (MN) tests. Also proliferating effect of the substance was investigated. Remeron didn't significantly cause chromosomal abnormalities and sister chromatid exchange while caused micronucleus at 40 µg/mL concentration and 24 h periodic time and increased proliferation index of the both 24 and 48 hours treated cells was decreased in a concentration manner. Also, exposing to the remeron for 24 and 48 hours leaded to a decrease in mitotic index and nucleus division index in the cells by concentration dependent manner. These findings showed that remeron did not have significantly genotoxic effects on human peripheral blood lymphocytes while it showed cytotoxic effects on the cells, which is the first report on genotoxic and cytotoxic properties of remeron.


Subject(s)
Adrenergic alpha-Antagonists/toxicity , Lymphocytes/drug effects , Mianserin/analogs & derivatives , Micronuclei, Chromosome-Defective/chemically induced , Serotonin Antagonists/toxicity , Sister Chromatid Exchange/drug effects , Adult , Cell Proliferation/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Female , Humans , Lymphocytes/pathology , Male , Mianserin/toxicity , Micronucleus Tests , Mirtazapine , Mitosis/drug effects , Mitotic Index , Risk Assessment , Time Factors , Young Adult
3.
Indian J Exp Biol ; 49(5): 339-42, 2011 May.
Article in English | MEDLINE | ID: mdl-21615057

ABSTRACT

Aqueous extract of C. collinus leaves inhibited norepinephrine induced contraction in guinea pig vas deferens and aortic strip in a dose-dependent manner. Inhibition of acetylcholine induced contraction in ileum was dose independent. C. collinus extract per se had no effect on isolated guinea pig vas deferens and aortic strip, but inhibited norepinephrine induced contraction in a dose-dependent manner probably by its antagonist action on alpha-adrenergic receptor. It had inconsistent effect on guinea pig ileum in vitro preparation.


Subject(s)
Adrenergic alpha-Antagonists/isolation & purification , Adrenergic alpha-Antagonists/toxicity , Ferns/chemistry , Animals , Aorta/drug effects , Guinea Pigs , Humans , Ileum/drug effects , In Vitro Techniques , India , Male , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Plant Extracts/toxicity , Plant Leaves/toxicity , Plant Poisoning/etiology , Plants, Toxic/chemistry , Plants, Toxic/toxicity , Vas Deferens/drug effects
4.
Arzneimittelforschung ; 60(10): 587-92, 2010.
Article in English | MEDLINE | ID: mdl-21125807

ABSTRACT

The present study describes the chemical synthesis and pharmacological evaluation of a series of 9-alkoxy-7H-furo[3,2-g]-chromen-7-ones. The pharmacological results of these compounds show that nine of them, given orally, reduced the immobility time in the forced swimming test. The results of the open-field test further confirmed that these compounds possessed an antidepressant-like effect. In the 5-hydroxytryptophan induced head-twitch test, 9-(3-chlorobenzyloxy)-7H-furo[3,2-g]chromen-7-one (3 m, 40 mg/kg p. o.) significantly increased the cumulative numberof head twitches. This finding suggested that the antidepressant-like profile seems to involve the serotonergic system as underlying mechanism.


Subject(s)
Antidepressive Agents/chemical synthesis , Antidepressive Agents/pharmacology , Furocoumarins/chemical synthesis , Furocoumarins/pharmacology , 5-Hydroxytryptophan/pharmacology , Adrenergic alpha-Antagonists/toxicity , Animals , Antidepressive Agents/toxicity , Behavior, Animal/drug effects , Biogenic Monoamines/metabolism , Drug Synergism , Hindlimb Suspension , Male , Mice , Motor Activity/drug effects , Structure-Activity Relationship , Swimming/psychology , Yohimbine/toxicity
6.
Anesth Prog ; 56(4): 123-7, 2009.
Article in English | MEDLINE | ID: mdl-20020792

ABSTRACT

OraVerse, an injectable formulation of phentolamine mesylate (PM), was recently approved by the U.S. Food and Drug Administration (FDA) for reversal of anesthesia of the lip and tongue and associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. Because PM had not been approved previously for submucosal administration, 2 Good Laboratory Practices (GLP) studies in dogs designed to investigate systemic toxicity and the local effects of single and repeated dosing of OraVerse on the inferior alveolar nerve and branches of the superior alveolar nerve and adjacent soft tissues after local administration were conducted. Systemic toxicity was measured by preinjection and postinjection clinical examinations, clinical chemistry, and gross and microscopic examinations of major organs after necropsy. No evidence of systemic toxicity was detected. Local nerve and adjacent tissue damage was assessed by conventional histopathology. Nerve degeneration was evident in 1 animal. Mild perineural inflammation adjacent to the inferior alveolar nerve and inflammatory exudates were observed in submucosal tissues in several animals. No changes were observed in the nerves at injection sites of dogs from any dose group that were considered directly related to the test articles. These data reveal that single and repeated intraoral administrations of OraVerse are well tolerated in beagle dogs.


Subject(s)
Adrenergic alpha-Antagonists/toxicity , Phentolamine/toxicity , Adrenergic alpha-Antagonists/administration & dosage , Anesthetics, Local/antagonists & inhibitors , Animals , Cranial Nerve Diseases/chemically induced , Dogs , Hematocrit , Hemoglobins/drug effects , Injections , Mandibular Nerve/drug effects , Maxillary Nerve/drug effects , Mouth Mucosa/drug effects , Nerve Degeneration/chemically induced , Nerve Fibers/drug effects , Neuritis/chemically induced , Organ Size , Phentolamine/administration & dosage , Random Allocation , Tissue Distribution , Vasodilator Agents/administration & dosage , Vasodilator Agents/toxicity
7.
Brain Res ; 1245: 108-15, 2008 Dec 15.
Article in English | MEDLINE | ID: mdl-18950605

ABSTRACT

The bed nucleus of stria terminalis (BST) has a tonic modulating role on the baroreflex parasympathetic component. In the present study, we verified that local BST-adrenoceptors modulate baroreflex-evoked bradycardiac responses in unanesthetized rats. Bilateral microinjection of the selective alpha(1)-adrenoceptor antagonist WB4101 (15 nmol/100 nL) into the BST increased the gain of reflex bradycardia in response to mean arterial pressure increases caused by intravenous (i.v.) infusion of phenylephrine, suggesting that BST alpha(1)-adrenoceptors modulate baroreflex bradycardiac response. Bilateral microinjection of either the selective alpha(2)-adrenoceptor antagonist RX821002 (15 nmol/100 nL) or the non-selective beta-adrenoceptor antagonist propranolol (15 nmol/100 nL) into the BST had not affected baroreflex bradycardia. Animals were pretreated intravenously with the cholinergic muscarinic receptor antagonist homatropine methyl bromide (HMB, 1.5 mg/Kg) to test the hypothesis that activation of alpha(1)-adrenoceptors in the BST would modulate the baroreflex parasympathetic component. Baroreflex bradycardiac responses evoked before and after BST treatment with WB4101 were no longer different when rats were pretreated with HMB. These results suggest that parasympathetic activation accounts for the effects saw after BST pharmacological manipulation and ruling out the possibility of a sympathetic withdraw. In conclusion, our data point out that local alpha(1)-adrenoceptors mediate the BST tonic influence on the baroreflex bradycardiac response modulating parasympathetic cardiac activity.


Subject(s)
Baroreflex/physiology , Parasympathetic Nervous System/physiology , Receptors, Adrenergic, alpha/physiology , Septal Nuclei/physiology , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic alpha-Antagonists/toxicity , Animals , Baroreflex/drug effects , Blood Pressure/drug effects , Blood Pressure/physiology , Bradycardia/chemically induced , Bradycardia/physiopathology , Dioxanes/administration & dosage , Dioxanes/pharmacology , Heart Rate/drug effects , Heart Rate/physiology , Male , Microinjections , Parasympathetic Nervous System/drug effects , Rats , Rats, Wistar , Receptors, Adrenergic, alpha/metabolism , Septal Nuclei/cytology , Septal Nuclei/drug effects , Tropanes/administration & dosage , Tropanes/toxicity
9.
Interact Cardiovasc Thorac Surg ; 7(5): 916-8, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18573847

ABSTRACT

Phenoxybenzamine, an irreversible alpha-adrenoceptor antagonist, is used as a topical treatment against catecholamine-induced contraction in radial artery bypass grafts. Published data suggest that a wide range of phenoxybenzamine doses may be equally effective. This study aimed to investigate whether lower doses of phenoxybenzamine would benefit grafts by better preserving endothelium. To this end human vascular endothelial cells were isolated from sections of radial artery or saphenous vein, and treated with phenoxybenzamine for 30 min. Cells were then washed free of drug and viability assayed using a resazurin-based toxicology assay or returned to culture for assay at 24 h. Phenoxybenzamine treatment showed a dose-dependent effect on cell viability over several clinically employed concentrations. Concentrations above 0.1 mM led to a loss of viability, which became more pronounced with time. The loss of viability was shown to be independent of the carrier used, as results were identical when phenoxybenzamine was dissolved in dimethylsulphoxide, which alone did not affect viability. Changes in pH alone were also not sufficient to affect viability. In conclusion, phenoxybenzamine treatment is likely to cause damage to graft endothelium if employed at concentrations above 0.1 mM (0.03 mg/ml). Phenoxybenzamine may be safely used at lower doses with no potential loss of endothelial cell viability.


Subject(s)
Adrenergic alpha-Antagonists/toxicity , Endothelial Cells/drug effects , Phenoxybenzamine/toxicity , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Endothelial Cells/pathology , Humans , Time Factors
10.
Bioorg Med Chem ; 15(24): 7765-72, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-17870537

ABSTRACT

A variety of tropane derivatives 14a-g were prepared via the reaction of the alcohol analogs 12a and 12b with substituted fluorobenzenes 13a-f. The prepared compounds were tested for their activity and selectivity toward the norepinephrine transporter (NET) and serotonin transporter (SERT) using yohimbine-induced mortality and 5-hydroxytryptophan-induced neurotoxicity in mice, respectively. All the tested compounds were found to be NE and 5-HT reuptake inhibitors except 14d which exhibited selective 5-HT reuptake inhibition activity.


Subject(s)
Norepinephrine Plasma Membrane Transport Proteins/metabolism , Norepinephrine/pharmacology , Selective Serotonin Reuptake Inhibitors/chemical synthesis , Serotonin Plasma Membrane Transport Proteins/metabolism , Serotonin/pharmacology , Tropanes/chemical synthesis , 5-Hydroxytryptophan/toxicity , Adrenergic alpha-Antagonists/toxicity , Animals , Citalopram/chemical synthesis , Citalopram/chemistry , Clomipramine/chemical synthesis , Clomipramine/chemistry , Crystallography, X-Ray , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Fluoxetine/chemical synthesis , Fluoxetine/chemistry , Mice , Molecular Structure , Norepinephrine Plasma Membrane Transport Proteins/drug effects , Serotonin Plasma Membrane Transport Proteins/drug effects , Selective Serotonin Reuptake Inhibitors/pharmacology , Tropanes/chemistry , Tropanes/pharmacology , Yohimbine/antagonists & inhibitors , Yohimbine/toxicity
11.
Yakugaku Zasshi ; 126 Spec no.: 247-56, 2006 Mar.
Article in Japanese | MEDLINE | ID: mdl-16518090

ABSTRACT

The toxicity profile of silodosin, a selective alpha(1A)-adrenoceptor antagonist, was evaluated. The lethal doses were 800 mg/kg in rats and 1500 mg/kg in dogs. Repeated-dose studies revealed fatty degeneration of hepatocytes and an induction of drug-metabolizing enzymes at 15 mg/kg/day or more in male rats, mammary gland hyperplasia at 60 mg/kg/day or more in female rats, and degeneration of the seminiferous tubular epithelium at 25 mg/kg/day or more only in young dogs. Silodosin was negative in all mutagenicity studies, except for a weak positive in a chromosomal aberration assay conducted without metabolic activation. In carcinogenicity studies, mammary gland tumors and pituitary adenomas were increased in female mice given 150 mg/kg/day or more and 400 mg/kg/day respectively, while thyroid follicular cell carcinoma was increased in male rats given 150 mg/kg/day. Reproductive studies in rats revealed a decreased male fertility at 20 mg/kg/day or more and a prolonged estrous cycle at 60 mg/kg/day or more. Silodosin did not exhibit any teratogenic potential in either rats or rabbits, and had no effects on the postnatal development of rat offspring. In safety pharmacology studies, silodosin produced no severe effects on the central nervous, cardiovascular, or respiratory systems. In conclusion, silodosin exhibited adequate safety margins between the clinically recommended dose and those at which toxic effects or safety pharmacological changes were detected. As a new therapeutic drug for the micturition difficulties caused by benign prostatic hyperplasia, silodosin should have few serious side effects in clinical use.


Subject(s)
Adrenergic alpha-Antagonists/toxicity , Indoles/toxicity , Toxicity Tests , Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic alpha-Antagonists/pharmacology , Animals , Cricetinae , Dogs , Drug-Related Side Effects and Adverse Reactions , Female , Guinea Pigs , Indoles/administration & dosage , Indoles/pharmacology , Lethal Dose 50 , Male , Mice , Pregnancy , Rabbits , Rats
12.
Toxicol Pathol ; 32(5): 558-66, 2004.
Article in English | MEDLINE | ID: mdl-15603540

ABSTRACT

Phentolamine is a reversible competitive alpha-adrenergic antagonist with similar affinities for alphal and alpha2 receptors. It has a long history of safe clinical use, and was developed as a potential therapy for male erectile dysfunction because of its capacity to increase the arteriolar blood flow to the corpora cavernosa. Phentolamine mesylate was administered to rats by oral gavage at daily doses of 10, 50, and 150 mg/kg for 24 months. A dose-related increase in mortality, ascribed to an exaggerated pharmacologic effect, was seen at high doses. Systemic exposure as measured by plasma drug concentration increased with dose and duration of dosing and slight drug accumulation occurred, particularly in high-dose males. In the treated groups, 10 males and 1 female were diagnosed with hibernomas, neoplasms of brown adipose tissue, which appeared in the thoracic cavity or retroperitoneal area as circumscribed, tan to reddish-brown lobulated masses. Histologically, the masses were well circumscribed with variably sized lobules defined by a rich capillary network and consisted of closely apposed oval to polygonal cells with large amounts of cytoplasm and a centrally located nucleus. The cytoplasm's appearance varied from multivacuolated to univacuolated to granular eosinophilic. In a few cases, neoplastic emboli were observed in capsular vessels. Ultrastructurally, the neoplastic cells contained numerous mitochondria with transverse parallel cristae that occupied over 60% of the cytoplasm and lipid droplets. This study documents the previously unreported development of hibernomas in rats treated with phentolamine mesylate.


Subject(s)
Adrenergic alpha-Antagonists/toxicity , Carcinogens/toxicity , Lipoma/chemically induced , Phentolamine/toxicity , Retroperitoneal Neoplasms/chemically induced , Thoracic Neoplasms/chemically induced , Administration, Oral , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic alpha-Antagonists/blood , Animals , Carcinogenicity Tests , Carcinogens/administration & dosage , Dose-Response Relationship, Drug , Female , Lipoma/pathology , Male , Mitochondria/drug effects , Mitochondria/ultrastructure , Phentolamine/administration & dosage , Phentolamine/blood , Rats , Rats, Sprague-Dawley , Retroperitoneal Neoplasms/pathology , Thoracic Neoplasms/pathology
13.
Biol Psychiatry ; 55(11): 1082-9, 2004 Jun 01.
Article in English | MEDLINE | ID: mdl-15158427

ABSTRACT

BACKGROUND: Brain noradrenaline is involved in footshock stress-induced reinstatement of drug seeking in a rat relapse model. We studied whether yohimbine, an alpha-2 adrenoceptor antagonist that increases noradrenaline release and induces anxiety-like responses in human and nonhuman subjects, would reinstate methamphetamine seeking in rats. METHODS: In experiment 1, the effect of yohimbine (1.25-2.5 mg/kg) on reinstatement was compared with that of intermittent footshock (5 min;.2-.6 mA) in rats that were trained to lever press for intravenous methamphetamine (9-11 days) and subsequently underwent 7 days of extinction training. In experiment 2, the effect of yohimbine on reinstatement of drug seeking was determined during early (1 day) and late (21 or 51 days) withdrawal periods. On the test days, rats were first given 3-hour extinction sessions and were then tested for reinstatement induced by yohimbine. RESULTS: In experiment 1, both yohimbine and footshock stress reinstated methamphetamine seeking after extinction. In experiment 2, extinction responding was higher after 21 or 51 withdrawal days than after 1 withdrawal day. In contrast, no significant time-dependent changes in yohimbine-induced reinstatement were observed. CONCLUSIONS: Results indicate that yohimbine is a potent stimulus for reinstatement of methamphetamine seeking in a rat relapse model.


Subject(s)
Behavior, Addictive/chemically induced , Methamphetamine , Substance-Related Disorders/etiology , Yohimbine/toxicity , Adrenergic alpha-Antagonists/toxicity , Animals , Behavior, Addictive/metabolism , Behavior, Addictive/psychology , Behavior, Animal , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Electroshock/methods , Extinction, Psychological/physiology , Male , Models, Animal , Rats , Rats, Long-Evans , Self Administration , Substance-Related Disorders/psychology , Time Factors
14.
Neuropsychopharmacology ; 29(4): 686-93, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14872205

ABSTRACT

Converging evidence suggests a role for noradrenergic mechanisms in stress-induced reinstatement of cocaine seeking in animals. Yohimbine, an alpha(2)-adrenoceptor antagonist, is known to be anxiogenic and induce stress-related responses in humans and animals. Here, we tested the ability of yohimbine to reinstate cocaine-seeking behavior and induce behavioral and physiological signs characteristic of stress in squirrel monkeys. Monkeys were trained to self-administer cocaine under a second-order schedule of i.v. drug injection. Drug seeking subsequently was extinguished by substituting saline for cocaine injections and omitting the cocaine-paired stimulus. The ability of yohimbine and the structurally distinct alpha(2)-adrenoceptor antagonist RS-79948 to reinstate cocaine-seeking behavior was assessed by administering priming injections immediately before test sessions in which the cocaine-paired stimulus was either present or absent. Priming injections of yohimbine (0.1-0.56 mg/kg, i.m.) or RS-79948 (0.01-0.1 mg/kg, i.m.) induced dose-related reinstatement of cocaine-seeking behavior. The magnitude of yohimbine-induced reinstatement was similar regardless of the presence or absence of the cocaine-paired stimulus. Yohimbine also significantly increased salivary cortisol levels, a physiological marker of stress, as well as scratching and self-grooming, behavioral markers of stress in nonhuman primates. In drug interaction experiments, pretreatment with the alpha(2)-adrenoceptor agonist clonidine (0.1-0.3 mg/kg, i.m.) dose-dependently inhibited yohimbine-induced reinstatement of cocaine seeking. In contrast, pretreatment with the dopamine receptor antagonist flupenthixol failed to inhibit yohimbine-induced reinstatement of cocaine seeking. The results show that pharmacological blockade of alpha(2)-adrenoceptors can induce reinstatement of cocaine-seeking behavior and characteristic stress responses in squirrel monkeys, providing a potentially useful model of stress-induced relapse to drug seeking.


Subject(s)
Adrenergic alpha-Antagonists/toxicity , Behavior, Addictive/chemically induced , Behavior, Animal/drug effects , Cocaine-Related Disorders/etiology , Adrenergic alpha-Agonists/pharmacology , Analysis of Variance , Animals , Behavior, Addictive/etiology , Clonidine/pharmacology , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Exploratory Behavior/drug effects , Extinction, Psychological/drug effects , Flupenthixol/pharmacology , Hydrocortisone/metabolism , Motor Activity/drug effects , Saimiri , Self Administration/methods , Serine Endopeptidases/drug effects , Time Factors , Vocalization, Animal/drug effects , Yohimbine/toxicity
15.
Toxicology ; 186(3): 181-9, 2003 Apr 22.
Article in English | MEDLINE | ID: mdl-12628311

ABSTRACT

Ethylene dibromide (EDB) has been used as a model compound for eliciting hepato- and nephrotoxicity. Conjugation with glutathione (GSH) has been shown to play a role in the bioactivation of EDB. The aim of this study was to determine whether activation of alpha(1)-adrenergic receptors, which causes a decrease in cellular GSH levels, could modulate the nephrotoxicity of EDB. For this purpose, male ICR mice were treated with EDB and/or the alpha-adrenergic agonist, phenylephrine (Pe), or the alpha-adrenergic antagonist, phentolamine (Phe). Animals treated with EDB (40 mg/kg, i.p.) had a 9.3-fold increase in urinary gamma-glutamyltranspeptidase (GGTP: EC 2.3.2.2) activity and a 38% decrease in renal non-protein bound sulfhydryl (NPSH) levels; however, animals co-treated with EDB and Pe (50 mg/kg, i.p.) exhibited a 27.8-fold increase in urinary GGTP activity and a 60% decrease in NPSH levels. The enhanced presence of urinary GGTP and decrease in cellular levels of NPSH was nearly blocked by treating animals concomitantly with EDB and Phe (10 mg/kg, i.p.) or EDB, Pe, and Phe. Histopathological examination revealed the enhanced degree of tissue damage and necrosis following treatment with EDB and Pe, and the protective effect of Phe at ameliorating EDB toxicity. These results indicate that factors that can influence alpha-adrenergic receptors may be critical in assessing dose-response data used in the risk assessment process.


Subject(s)
Adrenergic alpha-1 Receptor Agonists , Adrenergic alpha-Agonists/toxicity , Ethylene Dibromide/toxicity , Insecticides/toxicity , Kidney Diseases/chemically induced , Adrenergic alpha-Antagonists/toxicity , Animals , Catecholamines/blood , Drug Synergism , Kidney/drug effects , Kidney/enzymology , Kidney/metabolism , Kidney Diseases/enzymology , Kidney Diseases/pathology , Male , Mice , Mice, Inbred ICR , Phentolamine/toxicity , Phenylephrine/toxicity , Sulfhydryl Compounds/metabolism , gamma-Glutamyltransferase/urine
16.
Ophthalmic Res ; 33(6): 345-52, 2001.
Article in English | MEDLINE | ID: mdl-11721188

ABSTRACT

PURPOSE: To compare the corneal toxicity of xylazine (XYL)/ketamine (KET) with that of clonidine (CLO)/KET in the rat, in the presence or not of the alpha(2)-adrenergic antagonist yohimbine (YOH). METHODS: XYL (10 mg/kg) and CLO (0.15 mg/kg) were administered subcutaneously in the rat in combination with KET (50 mg/kg), in the presence or not of YOH (2 mg/kg). RESULTS: The corneas immediately lost transparency and luster, but recovered within 120 min. By both light and electron microscopy, a marked stromal edema and alterations of all layers were observed. In addition, XYL/KET altered the permeability of the cornea as indicated by the augmented levels of (14)C-indomethacin, topically administered 30 min after the anesthetic combination. CONCLUSIONS: The mechanism of the corneal toxicity of XYL and CLO in the rat is unclear but we speculate that: (a) proptosis and inhibition of normal blinking did not play a major role because topical application of hyaluronic acid did not protect against it; corneal decompensation, edema and opacification could be due to (b) osmotic or (c) mechanical endothelial stress: the first resulting from the sudden increase of the glucose concentration in the aqueous humor due to the well-known inhibition of insulin release by alpha(2)-adrenergic agonists, and the second from the acute elevation of intraocular pressure caused by these alpha(2)-adrenergic mydriatics in the rat; (d) addition, XYL and CLO could act by directly interacting with local alpha(2)- or, possibly, alpha(1)-adrenergic receptors, whose function is still not clear but probably essential for corneal homeostasis.


Subject(s)
Anesthetics, Combined/toxicity , Clonidine/toxicity , Cornea/drug effects , Corneal Edema/chemically induced , Ketamine/toxicity , Xylazine/toxicity , Adrenergic alpha-Agonists/toxicity , Adrenergic alpha-Antagonists/toxicity , Anesthetics, Dissociative/toxicity , Animals , Cornea/ultrastructure , Corneal Edema/pathology , Corneal Opacity/chemically induced , Corneal Opacity/pathology , Male , Rats , Rats, Long-Evans , Yohimbine/toxicity
17.
Biol Pharm Bull ; 23(12): 1445-9, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11145175

ABSTRACT

Orthostatic hypotension was produced in urethane-anesthetized rabbit by a combination of chlorpromazine (0.1 mg/kg, i.v.) and 45 degrees head-up tilt. The effect of midodrine (1 and 3 mg/kg, i.d.) was investigated in comparison with amezinium (10 and 30 mg/kg, i.d.), etilefrine (10 and 30 mg/kg, i.d.) and droxidopa (30 and 100 mg/kg, i.d.). The higher doses of each drug significantly mitigated the chlorpromazine-induced orthostatic hypotension, while none of the lower doses caused a significant effect. The effect of midodrine developed most rapidly; a significant effect was observed 25 min after administration. The order of onset time was midodrine < etilefrine < amezinium < droxidopa. The effect of droxidopa was significant only at 130 to 160 min after administration. The amplitude of effect was in the following order; midodrine = droxidopa > or = etilefrine > amezinium. Midodrine (3 mg/kg, i.d.) mitigated orthostatic hypotension induced by prazosin (0.1 mg/kg, i.v.), but not by pentolinium (0.6 mg/kg, i.v.). It is suggested that midodrine competes with chlorpromazine at alpha1-adrenoceptors and subsequently recovers reflex vasoconstriction. Midodrine may be useful to protect patients with impaired baroreflex activity from accidental orthostatic hypotension during treatment with neuroleptics.


Subject(s)
Adrenergic alpha-Agonists/pharmacology , Antipsychotic Agents/toxicity , Chlorpromazine/toxicity , Hypotension, Orthostatic/drug therapy , Midodrine/pharmacology , Sympathomimetics/pharmacology , Adrenergic alpha-Antagonists/toxicity , Animals , Antihypertensive Agents/toxicity , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Droxidopa/pharmacology , Drug Administration Routes , Drug Interactions , Duodenum , Etilefrine/pharmacology , Hypotension, Orthostatic/chemically induced , Male , Pentolinium Tartrate/toxicity , Prazosin/toxicity , Pyridazines/pharmacology , Rabbits
18.
Eur J Pharmacol ; 379(1): 47-52, 1999 Aug 20.
Article in English | MEDLINE | ID: mdl-10499370

ABSTRACT

N(G)-(Nitro-L-arginine (L-NOARG), an inhibitor of nitric oxide synthase, induces catalepsy in mice. The objective of the present work was to investigate if serotonergic drugs are able to modulate this effect. Results showed that the cataleptogenic effect of L-NOARG (40 mg/kg) in male albino-Swiss mice was enhanced by pre-treatment with (+)-N-tert-butyl-3-(4-[2-methoxyphenyl]piperazin-1-yl)-2-phenylpro panamide ((+)-WAY-100135, 5 or 10 mg/kg), a 5-HT1A-selective receptor antagonist, and by ketanserin (5 or 10 mg/kg), a 5-HT2A receptor and alpha1-adrenoceptor antagonist. Prazosin (3 or 5 mg/kg), an alpha1-adrenoceptor antagonist, and endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3yl)-2,3-dihydro-3,3-dimet hyl-indole-1-carboxamide HCl (BRL-46470A, 0.05 or 0.5 mg/kg), a 5-HT3 receptor antagonist, did not interfere with L-NOARG-induced catalepsy. Ritanserin (3 or 10 mg/kg), a 5-HT2A and 5-HT2C receptor antagonist, tended to enhance the effect of L-NOARG. These results confirm that interference with the formation of nitric oxide induces catalepsy in mice, and suggest that this effect is modulated by 5-HT1A and 5-HT2A receptors.


Subject(s)
Bridged Bicyclo Compounds, Heterocyclic/toxicity , Enzyme Inhibitors/toxicity , Indoles/toxicity , Nitric Oxide Synthase/metabolism , Nitric Oxide/metabolism , Nitroarginine/toxicity , Serotonin Antagonists/toxicity , Adrenergic alpha-Antagonists/toxicity , Animals , Catalepsy/etiology , Dose-Response Relationship, Drug , Drug Synergism , Ketanserin/toxicity , Male , Mice , Piperazines/toxicity , Prazosin/toxicity , Ritanserin/toxicity , Time Factors
19.
J Pharm Pharmacol ; 49(10): 1019-24, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9364413

ABSTRACT

The antinociceptive and antidepressant effects of two pyrazolotriazine derivatives, 2-phenyl-3,3a-dihydro-4-oxo-5-(4-phenylpiperazin-1-yl) methyl-pyrazolo[1,5-d][1,2,4]-triazine (SM1) and 2-phenyl-3,3a-dihydro-4-oxo-5-[4-(4-fluorophenyl)piperazin-1-yl] methylpyrazolo[1,5-d][1,2,4] triazine (SM3) have been investigated in mice using classical pharmacological tests. The intraperitoneal LD50 values of SM1 and SM3 were 253.4 and 218.8 mg kg-1 respectively. SM1 and SM3 showed analgesic properties in the phenylbenzoquinone-induced abdominal constriction test (ED50 approximately 10-15 mg kg-1, i.p.) and in the hot-plate test. The antinociceptive effects of the triazines were significantly reduced by administration of naloxone (1 and 3.2 mg kg-1, s.c.) and yohimbine (1 mg kg-1, p.o.). Acute intraperitoneal administration of both compounds (1 mg kg-1 SM1 or 1.5 mg kg-1 SM3) potentiated morphine (0.15 mg kg-1, s.c.) analgesia in the phenylbenzoquinone test. Although this synergistic activity was not reversed by methysergide (0.5 mg kg-1, i.p.), the analgesic activity of both compounds was enhanced by administration of 5-hydroxytryptophan (50 mg kg-1, i.p.) in conjunction with carbidopa (25 mg kg-1, i.p.). Furthermore, neither compound (at 100 mg kg-1, i.p.) significantly reduced the duration of immobility of mice in the forced swimming test, and both (at 75 mg kg-1, i.p.) were ineffective at enhancing the toxic effects of yohimbine (30 mg kg-1, s.c.). Only SM3 (ED50 = 74.5 mg kg-1, i.p.) significantly antagonized reserpine (2.5 mg kg-1, i.p.)-induced ptosis. Thus, the results suggest that SM1 and SM3 have antinociceptive properties related to co-involvement of opioidergic and alpha 2-adrenoceptor mechanism without associated antidepressant properties.


Subject(s)
Analgesics/pharmacology , Antidepressive Agents/pharmacology , Pyrazoles/pharmacology , Triazines/pharmacology , Adrenergic alpha-Antagonists/pharmacology , Adrenergic alpha-Antagonists/toxicity , Analgesics, Opioid/pharmacology , Animals , Central Nervous System Depressants/pharmacology , Drug Interactions , Immobilization , Male , Mice , Morphine/pharmacology , Narcotic Antagonists/pharmacology , Pain Measurement/drug effects , Pyrazoles/toxicity , Reaction Time/drug effects , Serotonin Antagonists/pharmacology , Triazines/toxicity , Yohimbine/pharmacology , Yohimbine/toxicity
20.
Reprod Toxicol ; 11(4): 627-31, 1997.
Article in English | MEDLINE | ID: mdl-9241685

ABSTRACT

Our objective was to investigate ejaculation and transport of sperm in the reproductive tract of male rats treated with an alpha-adrenergic receptor antagonist. Males were dosed (s.c.) with vehicle or 1.4 mg/kg prazosin. Sperm recovered in utero and ex vivo from the vas deferens and cauda epididymis were evaluated. Mating behavior and sperm motility were unaffected by prazosin. Prazosin treated males ejaculated fewer sperm (12.58 +/- 8.12 vs. 110.5 +/- 29.15 million), and the distal vas deferens contained fewer sperm (2.72 +/- 0.84 vs. 24.42 +/- 3.25 million) relative to controls. Prazosin-treated males had more sperm in the cauda epididymis relative to controls indicating inhibition of sperm transport to the vas deferens. These data demonstrate that inhibition of sperm transport from the cauda epididymis to the distal vas deferens is related to low ejaculate sperm counts in prazosin treated rats.


Subject(s)
Adrenergic alpha-Antagonists/toxicity , Prazosin/toxicity , Sperm Motility/drug effects , Animals , Ejaculation/drug effects , Female , Male , Rats , Rats, Sprague-Dawley , Sperm Count
SELECTION OF CITATIONS
SEARCH DETAIL
...